Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration

Summary

Patients with PKAN will be treated with the iron chelator deferiprone for 18 months. Only patients who have completed the earlier study TIRCON2012V1 (NCT01741532), a double-blind placebo-controlled trial in which participants were randomized to receive either deferiprone or placebo for 18 months, are eligible to enroll.

Timeline

Start

2014-06

Primary completion

2018-03-16

Completion

2018-03-16

Drugs

Indications